Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DJF1S3
|
|||
| Drug Name |
BI 764524
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Diabetic retinopathy [ICD-11: 9B71.0; ICD-10: H36.0] | Phase 2 | [1] | |
| Company |
boehringer-ingelheim
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Semaphorin-3A (SEMA3A) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04424290) A First-in Human Trial to Study Safety and Tolerability of Single Rising Intravitreal dOses (Open Label, Non-randomized, Uncontrolled) and in Addition the Early Biological Response of Multiple intravitReal Dosing (Single-masked, raNdomized, Sham-controlled) of BI 764524 in panretinaL Photocoagulation (PRP) Treated proLiferative Diabetic Retinopathy (PDR) Patients With Diabetic Macular Ischemia (DMI) - the HORNBILL Study. U.S.National Institutes of Health. | |||
| REF 2 | HORNBILL: a phase I/IIa trial examining the safety, tolerability and early response of BI 764524 in patients with diabetic retinopathy and diabetic macular ischaemia-rationale, study design and protocol. Trials. 2022 Aug 17;23(1):669. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.